Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
2.830
-0.375 (-11.70%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2024. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$1,670,948
Market Cap
2.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -1 | -10.00% |
| Dec 31, 2023 | 10 | 4 | 66.67% |
| Dec 31, 2022 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
REVB News
- 5 weeks ago - Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire
- 6 weeks ago - Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire
- 6 weeks ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - Business Wire
- 2 months ago - Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire
- 2 months ago - Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval - Business Wire
- 3 months ago - Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - Business Wire
- 3 months ago - Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire
- 3 months ago - Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025 - Business Wire